Uterine Fibroids Treatment Devices Market Size, Share & Trends Analysis Report By Technology (Surgical Techniques, Laparoscopic Techniques), By Mode Of Treatment, By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global uterine fibroids treatment devices market size was estimated at USD 7.0 billion in 2024 and is anticipated to grow at a CAGR of 9.4% from 2025 to 2030. The increasing prevalence of uterine fibroids makes them one of the most common benign tumors in women of reproductive age. As the number of women diagnosed with fibroids continues to rise, the demand for effective treatment options also increases. Fibroids are mostly found in women between the ages of 30 and 40, a group that typically seeks less invasive and more efficient treatment solutions. As women in this age range become more aware of available options, they are more likely to explore advanced treatments. This trend further fuels the need for innovative medical devices to address fibroids effectively in the uterine fibroids treatment devices industry. 

Minimally invasive procedures, such as Uterine Artery Embolization (UAE), laparoscopic myomectomy, and High-intensity Focused Ultrasound (HIFU), are becoming more popular due to faster recovery times, fewer complications, and improved outcomes. Both patients and healthcare providers increasingly favor these treatments. In addition, innovations in non-surgical devices, such as MRI-guided Focused Ultrasound (MRgFUS) and robotic-assisted surgeries, are making procedures safer and more effective. For instance, in a report published in November 2023 by the National Library of Medicine, it was found that the incidence rate of uterine fibroids among female service members in the U.S. Armed Forces was 63.5 cases per 10,000 person-years from 2011 to 2022. 

Many women with uterine fibroids are concerned about preserving their fertility. Non-invasive and fertility-preserving treatments such as HIFU, UAE, and myomectomy are becoming more popular because they offer safer alternatives to traditional methods such as hysterectomy. Patients prefer these treatments due to their lower risks and quicker recovery times. Women are increasingly choosing options that avoid surgery, particularly those who wish to retain their ability to have children. This patient-centric approach is driving demand for less invasive treatments. As a result, the preference for these fertility-preserving options is contributing to the growth of the uterine fibroids treatment devices industry.

Technology Insights

The surgical techniques segment dominated the market with a revenue share of 34.0% in 2024, attributed to the increasing prevalence of uterine fibroids among women, necessitating effective surgical interventions. Advanced technology in surgical devices has enhanced the precision and safety of procedures, making them more appealing to healthcare providers and patients. In addition, the rising awareness about treatment options has encouraged women to seek surgical solutions, contributing to the segment robust performance. The preference for minimally invasive approaches also plays a crucial role, as these techniques typically offer shorter recovery times and reduced postoperative complications.

The ablation techniques segment is projected to grow at the highest CAGR of 10.4% over the forecast period, fueled by the increasing demand for minimally invasive treatment options that offer significant benefits such as reduced pain, shorter hospital stays, and quicker recovery times compared to traditional surgical methods. The rising incidence of chronic conditions that require ablation procedures further supports this trend. Moreover, advancements in ablation technologies have improved their effectiveness and safety profiles, making them a preferred choice for many patients. Increased awareness campaigns regarding the benefits of ablation treatments also contribute to their rapid adoption in the uterine fibroids treatment devices industry.

Mode of Treatment Insights

The invasive treatment segment dominated the market with the largest revenue share in 2024, attributed to its established efficacy in treating severe uterine fibroids. Patients often opt for invasive procedures when non-invasive options do not provide sufficient relief from symptoms. The high success rates associated with these treatments and advancements in surgical techniques have boosted their popularity among healthcare professionals and patients. In addition, as healthcare facilities continue to invest in advanced technologies, the quality and outcomes of invasive treatments are expected to improve further in the uterine fibroids treatment devices industry.

The non-invasive treatment segment is projected to grow significantly over the forecast period due to increasing patient preferences for procedures that minimize recovery time and discomfort. The growing awareness about non-invasive options has led to higher demand among women seeking alternatives to traditional surgery. Innovations in technology have also made non-invasive treatments more effective and accessible, attracting a broader patient base. As more healthcare providers adopt these techniques, their market presence is expected to expand significantly in the uterine fibroids treatment devices industry.

Regional Insights

North America uterine fibroids treatment devices market dominated the global market, with a revenue share of 48.2% in 2024, driven by high healthcare spending and advanced medical infrastructure. The region strong focus on research and development has led to significant innovations in treatment devices, enhancing their effectiveness and safety. In addition, a high prevalence of uterine fibroids among women in North America has resulted in increased demand for effective treatment solutions. The presence of key market players and their continuous efforts in product development further solidify North America leading position in this market.

U.S. Uterine Fibroids Treatment Devices Market Trends

The U.S. uterine fibroids treatment devices market dominated North America with a significant revenue share in 2024, fueled by advanced technology and increasing product innovations. Healthcare providers are increasingly adopting new technologies that improve patient outcomes and reduce recovery times. In addition, heightened awareness among patients regarding available treatment options has led to increased consultations and procedures for uterine fibroid management. Frequent regulatory approvals also mark the competitive landscape for novel devices, encouraging further investment in this sector.

Europe Uterine Fibroids Treatment Devices Market Trends

Europe uterine fibroids treatment devices market held a substantial market share in 2024, driven by rising healthcare expenditures and a growing emphasis on women's health issues. Increased collaboration between healthcare providers and device manufacturers has enhanced product offerings tailored to patient needs. Furthermore, ongoing clinical research into innovative treatment options continues to expand the range of available therapies, raising market growth. The regulatory environment in the region also supports advancements in medical technologies, promoting the adoption of new devices.

Asia Pacific Uterine Fibroids Treatment Devices Market Trends

Asia Pacific uterine fibroids treatment devices market is expected to register the highest CAGR of 10.2% over the forecast period, which can be attributed to increasing awareness about women's health issues and rising disposable incomes among consumers. As urbanization progresses, access to healthcare services improves, leading to high diagnosis rates of uterine fibroids. In addition, investments from private players in this region drive innovation and availability of advanced treatment options tailored for local populations.

The China uterine fibroids treatment devices market dominates the Asia Pacific with a significant revenue share in 2024, driven by a large population base and increasing uterine fibroids among women. Growing healthcare investments to improve women's health services are also contributing factors. As healthcare infrastructure develops, more women are likely to seek effective treatments for uterine fibroids, supporting the demand for innovative medical devices within China.

Key Uterine Fibroids Treatment Devices Company Insights

Some key companies operating in the market include Medtronic, Stryker, Boston Scientific Corporation, Insightec.; and CooperSurgical Inc. Companies are undertaking strategic initiatives, such as mergers, acquisitions, and product launches, to expand their market presence and address the evolving healthcare demands through uterine fibroids treatment devices market.

• Medtronic offers a variety of products, such as the TruClear hysteroscopic tissue removal system, which is designed to remove fibroids and other intrauterine abnormalities using mechanical resection, which minimizes scarring. In addition, the TruClear dense tissue shaver is available in mini sizes for effective tissue removal during procedures. The HysteroLux fluid management system ensures optimal uterine distention and fluid monitoring during surgeries, enhancing overall procedural safety and effectiveness.

• Stryker offers a range of products, such as the MyoSure hysteroscopic tissue removal system, designed to remove fibroids and other intrauterine tissue effectively. It utilizes a unique mechanism that minimizes damage to surrounding tissues. The MyoSure XL is an advanced version that allows for the resection of larger fibroids, providing versatility in treatment options.

Recent Developments

• In September 2024, Gynesonics launched new Smart OS software to enhance its ultrasound systems functionality and user experience. This innovative software upgrade provided advanced imaging capabilities and improved workflow efficiency for healthcare providers performing uterine fibroid treatments.

• In November 2022, Medtronic launched the TruClear and HysteroLux systems in India, enhancing the landscape of diagnostic and operative hysteroscopy. The TruClear system was introduced to facilitate the removal of intrauterine tissue, including fibroids, through a minimally invasive approach, while the HysteroLux fluid management system aimed to improve uterine distention and visibility during procedures.

Uterine Fibroids Treatment Devices Market Report Scope

Global Uterine Fibroids Treatment Devices Market Report Segmentation

This report forecasts global, regional, and country revenue growth and analyzes the latest industry trends in each sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the global uterine fibroids treatment devices market report based on technology, mode of treatment, and region:

• Technology Outlook (Revenue, USD Billion, 2018 - 2030)

  • Surgical Techniques

    • Hysterectomy

    • Myomectomy

  • Laparoscopic Techniques

    • Laparoscopic Myomectomy

    • Myolysis

  • Ablation Techniques

    • Microwave Ablation

    • Hydrothermal Ablation

    • Cryoablation

    • Ultrasound Ablation

      • High Intensity Focused Ultrasound (HIFU)

      • MRI-guided Focused Ultrasound (MRgFUS)

  • Embolization Techniques

• Mode of Treatment Outlook (Revenue, USD Billion, 2018 - 2030)

  • Invasive Treatment

  • Minimally Invasive Treatment

  • Non-invasive Treatment

• Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America

    • U.S.       

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Norway

    • Denmark

    • Sweden

    • Russia

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

    • Colombia

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait